Employer Healthcare Costs: How 6–8% Premium Hikes Reshape Insurers, PBMs, and Employers

Employers face 6–8% premium hikes this year

Employer-sponsored plans are set to rise roughly 6% to 8% in 2026, forcing companies to raise deductibles and out-of-pocket maximums for workers. This scale of increase matters because healthcare already consumes roughly 18%–19% of U.S. spending (the exact share varies by year and data source), and employers are the primary payers for roughly half of nonelderly Americans.

What happened: employers shift costs and shop vendors

Employers report rising drug prices, chronic conditions, and provider consolidation as the main drivers, and surveys show varying shares of major purchasers planning RFPs for 2026 — for example, the Pacific Business Group on Health reported 23% of its members conducting an RFP for pharmacy benefits in 2026, while some industry polls have reported higher figures. That level of procurement activity is the highest we have seen in recent cycles and signals meaningful revenue churn for insurers and PBMs.

In practice employers are raising deductibles and pushing more cost to workers, while also exploring plan redesigns, tighter pharmacy management, and alternative care pathways. Those moves are already changing how premiums and benefit design are negotiated at renewal, with multi-year deals increasingly contingent on pharmacy carve-outs and utilization controls.

Why it matters: pharmacy and utilization are changing the economics

Pharmacy spend is the single most volatile line item, driven by GLP-1 weight-loss and diabetes drugs from companies like Eli Lilly (LLY) and Novo Nordisk (NVO). These therapies have materially increased employer pharmacy trend for many purchasers; in some cases, employers report pharmacy trend moving from low single digits into the high single digits or low double digits.

Beyond drugs, behavioral health utilization and hospital pricing amplify cost pressure; hospital prices remain materially above Medicare benchmarks, and labor shortages continue to push operating expenses higher. When core inputs rise faster than wages, employers either cut benefits, increase employee share, or demand vendors deliver measurable savings, and reported RFP activity (survey estimates vary) shows buyers are choosing the third option.

Historically, when employers leaned on vendors in the 2010s and early 2020s, winners were integrated platforms that could bundle pharmacy, care management, and data analytics. UnitedHealth (UNH) via Optum and CVS Health (CVS) with its Aetna and CVS Caremark assets can deploy those levers at scale, and that structural advantage matters when renewals are driven by 6–8% trend assumptions.

The bull case: integrated managers capture renewals and margins

Bull investors should like companies that can demonstrably cut trend by several percentage points through tighter drug management and care steering. UnitedHealth (UNH) and CVS (CVS) have scale advantages; Optum and Caremark can negotiate rebates, implement utilization management, and direct patients to lower-cost sites, which may trim employer spend by a few percentage points in some cases, though published estimates vary and savings depend on contract terms and utilization controls.

Benefits technology and HSA providers stand to win too. Platforms such as HealthEquity (HQY) and telehealth players like Teladoc (TDOC) can help employers shift care into lower-cost channels, and investors can expect premium multiples to re-rate for vendors that can show per-member savings greater than 100 basis points.

The bear case: cost passthroughs and regulatory risk dent margins

Bears will point out that rising utilization and blockbuster drugs create structural headwinds that no vendor can eliminate entirely, and some employers will simply pass costs to employees, which reduces demand elasticity and limits vendor pricing power. If pharmacy trend remains in the high single digits or goes double-digit, insurers without integrated PBMs or clinical touchpoints will see margin compression.

Regulatory risk is real, with policymakers focused on affordability. Price controls, increased transparency rules, or limits on formulary steering could shave several points off PBM economics. Hospitals and health systems such as HCA Healthcare (HCA) could be vulnerable if payers successfully pressure price growth, and pure-play pharma exposure to policy changes is nontrivial for stocks like LLY and NVO.

What this means for investors: pick the managers, watch the drugmakers

Actionable takeaway 1, favor integrated care and PBM leaders. UnitedHealth (UNH) and CVS Health (CVS) are positioned to gain share as survey-reported rebid activity for 2026 varies, and investors should watch Optum and Caremark metrics in quarterly reports for evidence of contract wins and trend reduction.

Actionable takeaway 2, own benefits-tech and steering plays. HealthEquity (HQY) and Teladoc (TDOC) can help employers reduce spend by shifting care and managing HSAs, and a 1% improvement in medical trend across a large book can translate into outsized cash flow gains for these vendors.

Actionable takeaway 3, be selective on insurers and hospitals. Insurers without scale or a PBM face margin risk if pharmacy and hospital price growth outpace premium increases. Hospital operators like HCA (HCA) are exposed if payers accelerate narrow-network steering; monitor contract negotiations and admission volumes closely.

Actionable takeaway 4, monitor GLP-1 trends but respect policy risk. Eli Lilly (LLY) and Novo Nordisk (NVO) are driving the current pharmacy debate, and their growth could be curtailed by stricter benefit management or utilization controls, so treat recent high-growth narratives as conditional on payer access.

Concrete tickers to watch

• UNH — integrated care and PBM scale, primary beneficiary if employers rebid.
• CVS — PBM plus insured book makes cost management actionable at renewal.
• CI — Cigna with Express Scripts could capture PBM-led renewals.
• LLY, NVO — drug growth engines under scrutiny from employers and payers.
• HQY, TDOC — benefits tech and telehealth to help employers steer care.
• HCA — hospital exposure to payer steering and price pressure.

Investor takeaway: with employer-sponsored premiums rising 6% to 8% and survey-reported rebid activity for 2026 varying across polls, favor firms that can demonstrably bend pharmacy and care trend. That's a clear win for integrated PBMs and care platforms, and a clear warning for service providers that cannot show measurable, multi-year savings.